SCHEMBL6323675

SCHEMBL6323675

CC(CS)NS(=O)(=O)c1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.67
ALDH1A1 P00352 5/20 0.63
CYP1A2 P05177 1/20 0.63
CYP2C9 P11712 1/20 0.63
CYP2C19 P33261 1/20 0.63
POLB P06746 1/20 0.49
CA12 O43570 2/20 0.47
CA9 Q16790 2/20 0.47
CA2 P00918 2/20 0.47
TSHR P16473 1/20 0.47
MMP2 P08253 4/20 0.47
CA14 Q9ULX7 1/20 0.47
ADAMTS4 O75173 3/20 0.46
MMP13 P45452 3/20 0.44
MMP3 P08254 2/20 0.44
MMP1 P03956 2/20 0.44
MMP9 P14780 2/20 0.44
MMP7 P09237 1/20 0.44
NR3C1 P04150 1/20 0.44
CA1 P00915 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6323678 1.00 SMN1; SMN2 (0.67) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL6332239 0.86 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL6332241 0.86 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL6323466 0.84 CA2 (0.68) SMN1; SMN2ALDH1A1CA12CA9CA2
SCHEMBL6323465 0.84 CA2 (0.68) SMN1; SMN2ALDH1A1CA12CA9CA2
SCHEMBL3971671 0.83 SMN1; SMN2 (0.74) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL6329763 0.82 CA2 (0.54) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL6323690 0.82 CA2 (0.53) ALDH1A1CA12CA9CA2TSHR
SCHEMBL6329758 0.82 CA2 (0.54) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL6326224 0.82 NR3C1 (0.51) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors PHARMACIA CORPORATION 2005-01-20 US disclosed
US-6747027-B1 SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 PHARMACIA CORPORATION 2004-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors MMP12, MMP13, MMP3 SMN1; SMN2 2514/4885ALDH1A1 986/4885CYP1A2 2019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.